Glutamine is a crucial nutrient for cancer cell growth, and its metabolism is frequently dysregulated in malignancies. 18F-FGln is a PET tracer that targets this altered glutamine metabolism. However, there are currently limited studies on the diagnostic value of 18F-FGln PET/CT in various types of cancer. Therefore, this prospective study was conducted to investigate the value of 18F-FGln PET/CT in patients with various types of malignant tumors.
Patients with clinical suspicion or exclusion of primary or recurrent malignant tumors (such as glioma of the brain, liver cancer, gastric cancer, duodenal cancer, colorectal cancer, ovarian cancer, etc., where 18F-FDG is prone to false negatives and false positives)
Patients undergoing tumor staging or evaluating treatment effect using 18F-FDG PET/CT or 18F-FGln PET/CT to determine the most appropriate treatment strategy
Patients without other tumor history
Patients with good compliance, providing informed consent, and able to follow the research protocol
pregnant or lactating patients or patients under 18 years old
the subjects and their parents or legal representatives are unable or unwilling to provide written informed consent;
patients with poor compliance, unable to tolerate or cooperate with PET/CT examinations.
those who have undergone gastrointestinal barium meal examination within one week;